Trial Profile
A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT)for Primary Refractory and Relapsed Acute Myelogenous Leukemia.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Jan 2018
Price :
$35
*
At a glance
- Drugs Cytarabine/daunorubicin (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 12 Jan 2018 Status changed from active, no longer recruiting to completed.
- 24 Dec 2017 Status changed from discontinued to active, no longer recruiting.
- 01 Mar 2017 Planned End Date changed from 1 Mar 2011 to 1 Jun 2019.